|
Dr. Mather established Raven on pioneering research performed in her laboratory at Genentech. With more than 30 years of experience in cell culture and cell biology research, Dr. Mather is a recognized leader in the application of cell biology to technology and pharmaceutical product development. She has unusually broad experience that spans basic research in cancer biology and reproductive endocrinology as an Assistant Professor at The Rockefeller University to applied research in development and product discovery at Genentech. Prior to founding Raven, Dr. Mather was a Staff Scientist for 15 years at Genentech, engaged in all phases of drug discovery and development, from project conception through scale-up and the development of potential new products. Dr. Mather led or participated in 12 project teams that produced a number of Genentech's marketed products, including Herceptin�, a monoclonal antibody for treatment of patients with metastatic breast cancer; Activase�, a biosynthetic form of the human tissue plasminogen activator (t-PA) for treatment of heart attack, acute ischemic stroke, and acute massive pulmonary embolism; Pulmozyme�, an inhalation solution for management of cystic fibrosis; and Genentech's anti-IgE antibody currently in late-stage clinical trials for asthma. Dr. Mather's work led to a number of breakthroughs in cell technology and several key patents for Genentech, including serum-free media for the commercial production of t-PA and other products, genetically engineered production cell lines, several tissue progenitor cell lines, and use patents on several Genentech pipeline products. She also contributed to the design of the cell culture biomanufacturing processes used for commercial production of four of Genentech's marketed protein therapeutics. Dr. Mather is an inventor on 30 issued patents, the author of more than 150 publications, and the author or editor of five books on animal cell culture. She is on the board of directors of Healthcare Businesswomen's Association, and serves on the scientific advisory board of Springboard Enterprises as well as two bioscience companies. She received a PhD from the University of California, San Diego and was an NIH-INSERM exchange scientist in Lyon, France. | 